Anixa Biosciences (NASDAQ:ANIX) Upgraded at Zacks Research

Anixa Biosciences (NASDAQ:ANIX) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other research analysts also recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anixa Biosciences in a research note on Wednesday, June 17th. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Finally, Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Anixa Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Anixa Biosciences Stock Down 1.1%

Shares of Anixa Biosciences stock opened at $3.52 on Tuesday. The stock’s fifty day moving average is $2.86 and its two-hundred day moving average is $2.91. The company has a market capitalization of $119.75 million, a PE ratio of -11.35 and a beta of 0.59. Anixa Biosciences has a 52 week low of $2.32 and a 52 week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. As a group, research analysts anticipate that Anixa Biosciences will post -0.31 earnings per share for the current year.

Insider Activity at Anixa Biosciences

In other news, CEO Amit Kumar purchased 21,000 shares of the business’s stock in a transaction dated Friday, June 12th. The shares were purchased at an average price of $2.50 per share, for a total transaction of $52,500.00. Following the completion of the purchase, the chief executive officer owned 630,812 shares in the company, valued at approximately $1,577,030. This represents a 3.44% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders acquired a total of 28,836 shares of company stock worth $75,187 in the last 90 days. Company insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Segall Bryant & Hamill LLC purchased a new position in Anixa Biosciences during the 1st quarter valued at about $45,000. Renaissance Technologies LLC lifted its position in shares of Anixa Biosciences by 13.6% in the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after purchasing an additional 7,300 shares during the period. Kestra Advisory Services LLC boosted its stake in shares of Anixa Biosciences by 96.2% during the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after purchasing an additional 25,000 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Anixa Biosciences during the fourth quarter valued at approximately $161,000. Finally, Millennium Management LLC purchased a new position in Anixa Biosciences during the fourth quarter valued at approximately $38,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.